Evidence map›Paper›PMID 35215357›Full record

ArticlePharmaceuticals (Basel, Switzerland)2022

Potential Synergistic Antibiotic Combinations against Fluoroquinolone-Resistant

Ashish Kothari, Neeraj Jain, Shyam Kishor Kumar, Ankur Kumar, Karanvir Kaushal, Satinder Kaur, Atul Pandey, Amit Gaurav, Balram Ji Omar

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Age of Antibiotic Resistance in MDR/XDR Clinical Pathogen ofPharmaceuticals (Basel, Switzerland) · 2023
    Review
  4. Review
  5. Resistance genomics and molecular epidemiology of high-risk clones of ESBL-producingFrontiers in cellular and infection microbiology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Ashish KothariDepartment of Microbiology, All India Institute of Medical Sciences Rishikesh, Rishikesh 249203, India.
Neeraj JainDepartment of Medical Oncology, All India Institute of Medical Sciences Rishikesh, Rishikesh 249203, India.ORCID 0000-0002-3736-8621
Shyam Kishor KumarDepartment of Microbiology, All India Institute of Medical Sciences Deoghar, Deoghar 814152, India.
Ankur KumarDepartment of Microbiology, All India Institute of Medical Sciences Rishikesh, Rishikesh 249203, India.
Karanvir KaushalDepartment of Biochemistry, All India Institute of Medical Sciences Rishikesh, Rishikesh 249203, India.
Satinder KaurDepartment of Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India.
Atul PandeyDepartment of Ecology, Evolution and Behavior, The Hebrew University of Jerusalem, Jerusalem 9190401, Israel.ORCID 0000-0001-6954-6990
Amit GauravSatbiome, Dehradun 248007, India.ORCID 0000-0003-4657-394X
Balram Ji OmarDepartment of Microbiology, All India Institute of Medical Sciences Rishikesh, Rishikesh 249203, India.ORCID 0000-0001-7805-2730
All India Institute of Medical Sciences Rishikesh · INAll India Institute of Medical Sciences, Deoghar · INCentral Drug Research Institute · INHebrew University of Jerusalem · ILPost Graduate Institute of Medical Education and Research · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The rise in multiple-drug-resistant (MDR) phenotypes in Gram-negative pathogens is a major public health crisis.

Indexed as

PMQRpolymyxinsPseudomonas aeruginosaQRDRquinolonesresistantsynergy

Identifiers

PMID35215357
PMCPMC8880063
OpenAlexW4212991188

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.